The FDA on October 15, 2021, approved TECENTRIQ® (Atezolizumab) for adjuvant treatment following resection and platinum-based chemotherapy in patients with Stage II to IIIA Non-Small Cell Lung Cancer (NSCLC) whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. TECENTRIQ® is a product of Genentech, Inc.
Today, the FDA also approved the VENTANA PD-L1 (SP263) Assay (Ventana Medical Systems, Inc.) as a companion diagnostic device to select patients with NSCLC for adjuvant treatment with TECENTRIQ®.
